With Asia’s biopharma boom set to continue with impressive year-on-year growth, you can’t afford to ignore this lucrative market. BioPharma Asia Convention 2016 returns to Singapore, bringing you more content than ever before, offering you a truly one-stop shop for taking advantage of the region’s potential.
We’re bringing you more speakers and sessions than ever before, discussing the latest trends and developments in clinical trials, manufacturing, supply chain, partnering, pricing, policies and market access. On top of that, drug discovery tracks showcasing the latest discoveries in vaccines, biosimilars, antibodies, orphan drugs, and stem cells will ensure you leave with up-to-the-minute knowledge of the latest R&D developments.
Here are some highlights from our manufacturing track:
- Learn how to set up a new manufacturing plant in India
Join Dr GS Reddy, Senior Vice President, Indian Immunologicals Limited, as he shows you how Indian Immunologicals is a major player, and one of the lowest-cost vaccine manufacturers in the world. Among others, their most renowned product is the foot and mouth disease vaccine. In his presentation, Dr Reddy will share how his company set up new manufacturing capabilities, to achieve a capacity of 360 million doses per annum while maintaining the cost of the vaccine at 7.6 INR per dose (equivalent to approximately US 1.5 cents per dose).
- Overcome challenges in scaling up production
Dr Lucas Chan, Head of Advanced Therapy Production, NIHR Investigator in Cell and Gene Therapy, King’s College Hospital Clinical Research Facility will share how he worked to overcome scaling up challenges of lentiviral vectors for gene therapy beyond the Phase I barrier. Chan developed novel retroviral producer cell lines for gene therapy and recently gained approval for his work in genetically modified whole cell vaccines for acute myeloid leukemia. His team has also developed the first regulatory approved GMP compliant procedure in Europe, which manufactures the largest amount of Lenti and Retroviral vectors for clinical applications in Europe. With his responsibilities in overseeing the production of a range of other cellular therapies as IMPs including peptides and NK cell therapies, as well as the contract manufacture of a Dendritic Cell based vaccine for Glioblastoma Multiforme in a worldwide Phase III clinical trial, Chan’s sharing in both gene therapy and biologics manufacturing is a clear reason why you should join us at BioPharma Asia Convention 2016.
- Find the best way to balance cost and efficiency in downstream processing
Is single use technology the solution for your downstream challenges? It makes sense to adopt single use technology for smaller batch productions due to the removal of the bottleneck step in buffer preparation in downstream processes. However, the cost advantage declines when the protein load increases in production. In our pre-conference workshop, Merck will teach you the best way to balancing the cost and efficiency of downstream manufacturing by adopting a variable yet flexible process tailored according to your production scale.
About BioPharma Asia Convention 2016
The 9th BioPharma Asia Convention is the largest regional B2B event in the industry, bringing more than 1500 attendees annually. The 2016 program will be bigger than ever before, offering you more tracks, more content and more value. Our 7 premium conference tracks will explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines & infectious diseases, antibodies, orphan drugs, biosimilars, stem cells and more.